Detoxification as a primary treatment modality for chronic pain—Part II

Townsend Letter for Doctors and Patients, Feb-March, 2005 by Gina L. Nick

References

1. Marceau F, Regoli D. Bradykinin receptor ligands: Therapeutic perspectives. 2004; 3:845-852.

2. National Research Council. Biologic Markers in Immunotoxicology. Washington, DC: National Academy Press, 1996;70.

3. http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/R/ROS.html

4. Bigazzi, PE, Bureck, CL and Rose, NR. Antibodies to tissue-specific endocrine, gastrointestinal, and neurological antigens. In Manual of Clinical Laboratory Immunology, 3rd Ed., Rose, NR, Friedman, H and Fahey, JL. Washington, DC: American Society for Microbiology, 1986;762-770.

5. Wyngaarden, JB and Smith, LH, Cecil. Textbook of Medicine, 18th Ed. Philadelphia, PA: WB Saunders, 1988.

6. Watkins L, Maier s. Implications of immune-to-brain communications for sickness and pain. Proc Natl Acad Sci USA 1999; 96:7710-7713.

7. National Research Council. Environmental Neurotoxicity. Washington DC: National Academy Press, 1992;9-11.

8. Anger, WK. Neurobehavioral Toxicology. Baltimore, MD: Johns Hopkins University Press, 1986; 331-347.

9. Nick, G. Clinical Purification: A Complete Treatment and Reference Manual. Brookfield, WI: Longevity Through Prevention Publishing, 2001; 53-217.

by Gina L. Nick, PhD, ND

Chief Scientific Officer at Longevity Through Prevention, Inc.

Phone: 866-587-4622 x702 * Fax: 866-587-4622 * E-mail: drgina@LTPonline.com

P.O. Box 6936 * Laguna Niguel, California 92677 USA

www.LTPonline.com